US6048729A
(en)
*
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US5283187A
(en)
*
|
1987-11-17 |
1994-02-01 |
Brown University Research Foundation |
Cell culture-containing tubular capsule produced by co-extrusion
|
US5773286A
(en)
*
|
1987-11-17 |
1998-06-30 |
Cytotherapeutics, Inc. |
Inner supported biocompatible cell capsules
|
US5487739A
(en)
*
|
1987-11-17 |
1996-01-30 |
Brown University Research Foundation |
Implantable therapy systems and methods
|
US5158881A
(en)
*
|
1987-11-17 |
1992-10-27 |
Brown University Research Foundation |
Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
|
US5106627A
(en)
*
|
1987-11-17 |
1992-04-21 |
Brown University Research Foundation |
Neurological therapy devices
|
US5182111A
(en)
*
|
1987-11-17 |
1993-01-26 |
Boston University Research Foundation |
In vivo delivery of active factors by co-cultured cell implants
|
US5871472A
(en)
*
|
1987-11-17 |
1999-02-16 |
Brown University Research Foundation |
Planting devices for the focal release of neuroinhibitory compounds
|
US5786216A
(en)
*
|
1987-11-17 |
1998-07-28 |
Cytotherapeutics, Inc. |
Inner-supported, biocompatible cell capsules
|
US5418154A
(en)
*
|
1987-11-17 |
1995-05-23 |
Brown University Research Foundation |
Method of preparing elongated seamless capsules containing biological material
|
WO1990001969A1
(en)
*
|
1988-08-24 |
1990-03-08 |
Slepian Marvin J |
Biodegradable polymeric endoluminal sealing
|
US5011472A
(en)
*
|
1988-09-06 |
1991-04-30 |
Brown University Research Foundation |
Implantable delivery system for biological factors
|
WO1990015637A2
(en)
*
|
1989-06-21 |
1990-12-27 |
Brown University Research Foundation |
Neurological therapy system
|
WO1991000119A1
(en)
*
|
1989-06-30 |
1991-01-10 |
Baxter International Inc. |
Implantable device
|
US5100392A
(en)
*
|
1989-12-08 |
1992-03-31 |
Biosynthesis, Inc. |
Implantable device for administration of drugs or other liquid solutions
|
US5843892A
(en)
*
|
1989-12-18 |
1998-12-01 |
California Institute Of Technology |
Stimulation of nerve growth and/or vitality
|
US5269785A
(en)
*
|
1990-06-28 |
1993-12-14 |
Bonutti Peter M |
Apparatus and method for tissue removal
|
JP3657001B2
(en)
*
|
1990-10-19 |
2005-06-08 |
ニューヨーク・ユニバーシティ |
Methods of transplanting cells into the brain and therapeutic uses therefor
|
US5618531A
(en)
|
1990-10-19 |
1997-04-08 |
New York University |
Method for increasing the viability of cells which are administered to the brain or spinal cord
|
US5545223A
(en)
*
|
1990-10-31 |
1996-08-13 |
Baxter International, Inc. |
Ported tissue implant systems and methods of using same
|
US5713888A
(en)
*
|
1990-10-31 |
1998-02-03 |
Baxter International, Inc. |
Tissue implant systems
|
US5344454A
(en)
*
|
1991-07-24 |
1994-09-06 |
Baxter International Inc. |
Closed porous chambers for implanting tissue in a host
|
US5314471A
(en)
*
|
1991-07-24 |
1994-05-24 |
Baxter International Inc. |
Tissue inplant systems and methods for sustaining viable high cell densities within a host
|
WO1992007525A1
(en)
*
|
1990-10-31 |
1992-05-14 |
Baxter International Inc. |
Close vascularization implant material
|
JPH06505186A
(en)
*
|
1991-02-11 |
1994-06-16 |
オマーヤ,アユブ ケー. |
Spinal fluid-powered prosthesis
|
US5222982A
(en)
*
|
1991-02-11 |
1993-06-29 |
Ommaya Ayub K |
Spinal fluid driven artificial organ
|
US5800829A
(en)
*
|
1991-04-25 |
1998-09-01 |
Brown University Research Foundation |
Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
|
AU666118B2
(en)
*
|
1991-04-25 |
1996-02-01 |
Brown University Research Foundation |
Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
|
DK0586559T3
(en)
*
|
1991-05-21 |
1996-07-22 |
Univ Brown Res Found |
Hollow fibers and apparatus for use in their manufacture
|
WO1992020400A1
(en)
*
|
1991-05-24 |
1992-11-26 |
Sumitomo Pharmaceuticals Company, Limited |
Instrument for applying pharmaceutical to inside of brain
|
ATE161707T1
(en)
*
|
1991-06-28 |
1998-01-15 |
Univ Brown Res Found |
CAPSULE EXTRUSION SYSTEMS
|
US5232712A
(en)
*
|
1991-06-28 |
1993-08-03 |
Brown University Research Foundation |
Extrusion apparatus and systems
|
US6773458B1
(en)
*
|
1991-07-24 |
2004-08-10 |
Baxter International Inc. |
Angiogenic tissue implant systems and methods
|
US5453278A
(en)
*
|
1991-07-24 |
1995-09-26 |
Baxter International Inc. |
Laminated barriers for tissue implants
|
US6503277B2
(en)
*
|
1991-08-12 |
2003-01-07 |
Peter M. Bonutti |
Method of transplanting human body tissue
|
HU220795B1
(en)
*
|
1991-09-20 |
2002-05-28 |
Amgen Inc. |
Glialcell derived neurotrophic factor proteins and devices and pharmaceutical preparations for preventing and treating neural cell damage
|
US20040175795A1
(en)
*
|
1991-09-20 |
2004-09-09 |
Amgen Inc. |
Glial derived neurotrophic factor
|
JP3252361B2
(en)
*
|
1991-10-02 |
2002-02-04 |
ミルトン・エイチ・リプスキー |
Assays for treating cancer in vivo
|
US5792900A
(en)
*
|
1991-10-21 |
1998-08-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for producing and using homogenous neuronal cell transplants
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6063630A
(en)
*
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
NZ245015A
(en)
*
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
US5733761A
(en)
|
1991-11-05 |
1998-03-31 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
WO1993022360A1
(en)
*
|
1992-04-24 |
1993-11-11 |
The Polymer Technology Group, Inc. |
Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
|
DE69334150T2
(en)
*
|
1992-05-14 |
2008-03-13 |
Baylor College Of Medicine, Houston |
MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE, AND MOLECULAR SWITCHES FOR GENE THERAPY
|
DE69330640T2
(en)
*
|
1992-05-29 |
2002-07-04 |
Vivorx Inc |
MICRO-ENCLOSURE OF CELLS
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US5871985A
(en)
*
|
1992-09-28 |
1999-02-16 |
Brown University Research Foundation |
Particulate non cross-linked chitosan core matrices for encapsulated cells
|
CA2144059A1
(en)
*
|
1992-09-28 |
1994-04-14 |
Patrick Aebischer |
Chitosan matrices for encapsulated cells
|
US5383873A
(en)
*
|
1992-12-09 |
1995-01-24 |
Regents Of The University Of Minnesota |
Smooth muscle chemical pacemaker
|
US5753491A
(en)
*
|
1993-04-13 |
1998-05-19 |
Us Health |
Use of neuro-derived fetal cell lines for transplantation therapy
|
ES2170096T3
(en)
*
|
1993-04-13 |
2002-08-01 |
Us Gov Health & Human Serv |
USE OF NEURODERIVED FETAL CELLULAR LINES FOR TRANSPLANTATION THERAPY.
|
ES2145137T3
(en)
*
|
1993-04-27 |
2000-07-01 |
Cytotherapeutics Inc |
MEMBRANE FORMED BY AN ACRYLONITRILE BASED POLYMER.
|
US5698413A
(en)
*
|
1993-05-05 |
1997-12-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of evaluating chemotherapeutic agents in vivo
|
WO1995001203A2
(en)
*
|
1993-06-23 |
1995-01-12 |
Cytotherapeutics, Inc. |
Implantable membrane encapsulation apparatus
|
AU7568094A
(en)
*
|
1993-08-12 |
1995-03-14 |
Cytotherapeutics, Inc. |
Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
|
US5908623A
(en)
*
|
1993-08-12 |
1999-06-01 |
Cytotherapeutics, Inc. |
Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
|
WO1995006486A1
(en)
*
|
1993-09-03 |
1995-03-09 |
Government Of The United States Of America, Secretary Department Of Health And Human Services |
Treatment of human tumors by genetic transformation of human tumor cells
|
EP0670738A1
(en)
*
|
1993-09-24 |
1995-09-13 |
Baxter International Inc. |
Methods for enhancing vascularization of implant devices
|
JPH09505054A
(en)
*
|
1993-11-09 |
1997-05-20 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Compositions as homogeneous neuronal cell implants and methods of making and using these implants
|
US5550050A
(en)
*
|
1994-04-15 |
1996-08-27 |
Cytotherapeutics, Inc. |
Method for implanting encapsulated cells in a host
|
US6156305A
(en)
*
|
1994-07-08 |
2000-12-05 |
Baxter International Inc. |
Implanted tumor cells for the prevention and treatment of cancer
|
EP0774929A4
(en)
*
|
1994-07-22 |
2000-09-27 |
Univ Washington |
Methods for stereotactic implantation
|
US20030157074A1
(en)
*
|
1994-11-16 |
2003-08-21 |
Mitrani Eduardo N. |
Vitro micro-organs, and uses related thereto
|
US20030152909A1
(en)
*
|
1994-11-16 |
2003-08-14 |
Mitrani Eduardo N. |
In vitro micro-organs, and uses related thereto
|
AU4975996A
(en)
|
1995-02-10 |
1996-08-27 |
Matthew A Bergan |
Method and device for administering analgesics
|
WO1996032076A1
(en)
*
|
1995-04-11 |
1996-10-17 |
Baxter Internatonal Inc. |
Tissue implant systems
|
US7069634B1
(en)
|
1995-04-28 |
2006-07-04 |
Medtronic, Inc. |
Method for manufacturing a catheter
|
AU5545596A
(en)
*
|
1995-04-28 |
1996-11-18 |
Medtronic, Inc. |
Intraparenchymal infusion catheter system
|
US6132463A
(en)
|
1995-05-19 |
2000-10-17 |
Etex Corporation |
Cell seeding of ceramic compositions
|
US6060640A
(en)
*
|
1995-05-19 |
2000-05-09 |
Baxter International Inc. |
Multiple-layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue
|
US5681740A
(en)
*
|
1995-06-05 |
1997-10-28 |
Cytotherapeutics, Inc. |
Apparatus and method for storage and transporation of bioartificial organs
|
US5704910A
(en)
*
|
1995-06-05 |
1998-01-06 |
Nephros Therapeutics, Inc. |
Implantable device and use therefor
|
US5837234A
(en)
*
|
1995-06-07 |
1998-11-17 |
Cytotherapeutics, Inc. |
Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
|
WO1997010807A1
(en)
*
|
1995-09-22 |
1997-03-27 |
Gore Hybrid Technologies, Inc. |
Improved cell encapsulation device
|
US6184200B1
(en)
|
1995-09-28 |
2001-02-06 |
Amgen Inc. |
Truncated glial cell line-derived neurotrophic factor
|
US5731284A
(en)
*
|
1995-09-28 |
1998-03-24 |
Amgen Inc. |
Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
|
US5855613A
(en)
*
|
1995-10-13 |
1999-01-05 |
Islet Sheet Medical, Inc. |
Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change
|
DE69637842D1
(en)
*
|
1995-10-26 |
2009-04-02 |
Paul P Latta |
Induction of immunological tolerance
|
US5641749A
(en)
*
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
|
US5641750A
(en)
*
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
|
US6087129A
(en)
|
1996-01-19 |
2000-07-11 |
Betagene, Inc. |
Recombinant expression of proteins from secretory cell lines
|
US6110707A
(en)
*
|
1996-01-19 |
2000-08-29 |
Board Of Regents, The University Of Texas System |
Recombinant expression of proteins from secretory cell lines
|
US5741778A
(en)
*
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
US7138251B1
(en)
|
1996-04-22 |
2006-11-21 |
Amgen Inc. |
Polynucleotides encoding a neurotrophic factor receptor
|
US6455277B1
(en)
|
1996-04-22 |
2002-09-24 |
Amgen Inc. |
Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
DE69732711T2
(en)
*
|
1996-07-12 |
2006-03-16 |
Genentech, Inc., South San Francisco |
GAMMA-heregulin
|
ATE486937T1
(en)
|
1996-07-12 |
2010-11-15 |
Genentech Inc |
CHIMERIC HETEROMULTIMERIC ADHESINS
|
US6054142A
(en)
|
1996-08-01 |
2000-04-25 |
Cyto Therapeutics, Inc. |
Biocompatible devices with foam scaffolds
|
US6200589B1
(en)
|
1996-09-13 |
2001-03-13 |
The University Of Akron |
Biological implants of semipermeable amphiphilic membranes
|
AUPO251096A0
(en)
|
1996-09-23 |
1996-10-17 |
Cardiac Crc Nominees Pty Limited |
Polysiloxane-containing polyurethane elastomeric compositions
|
US8728536B2
(en)
*
|
1996-10-16 |
2014-05-20 |
Etex Corporation |
Chemotherapeutic composition using nanocrystalline calcium phosphate paste
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
EP2002846B1
(en)
|
1996-12-06 |
2017-01-25 |
Amgen Inc. |
Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
|
AUPO431596A0
(en)
|
1996-12-20 |
1997-01-23 |
Scientec Research Pty Ltd |
Apparatus and method for coating a material
|
AU748044B2
(en)
|
1997-01-16 |
2002-05-30 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
A device and method for performing a biological modification of a fluid
|
US6547787B1
(en)
|
1997-03-13 |
2003-04-15 |
Biocardia, Inc. |
Drug delivery catheters that attach to tissue and methods for their use
|
US6416510B1
(en)
*
|
1997-03-13 |
2002-07-09 |
Biocardia, Inc. |
Drug delivery catheters that attach to tissue and methods for their use
|
US6128537A
(en)
*
|
1997-05-01 |
2000-10-03 |
Medtronic, Inc |
Techniques for treating anxiety by brain stimulation and drug infusion
|
WO1998050525A1
(en)
*
|
1997-05-07 |
1998-11-12 |
Neuralstem Biopharmaceuticals |
Embryonic and adult cns stem cells
|
US6272370B1
(en)
|
1998-08-07 |
2001-08-07 |
The Regents Of University Of Minnesota |
MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
|
US6061587A
(en)
*
|
1997-05-15 |
2000-05-09 |
Regents Of The University Of Minnesota |
Method and apparatus for use with MR imaging
|
US6026316A
(en)
*
|
1997-05-15 |
2000-02-15 |
Regents Of The University Of Minnesota |
Method and apparatus for use with MR imaging
|
US7048716B1
(en)
|
1997-05-15 |
2006-05-23 |
Stanford University |
MR-compatible devices
|
ZA986077B
(en)
|
1997-07-09 |
2000-01-10 |
Genentech Inc |
ErbB4 receptor-specific neuregulin related ligands and uses therefor.
|
US6121415A
(en)
*
|
1997-07-09 |
2000-09-19 |
Genentech, Inc. |
ErbB4 receptor-specific neuregolin related ligands and uses therefor
|
US6994856B1
(en)
*
|
1997-07-24 |
2006-02-07 |
Genentech, Inc. |
ErbB4 receptor-specific neuregulin related ligands and uses therefor
|
DE69838584T2
(en)
|
1997-08-04 |
2008-06-26 |
Cell Genesys, Inc., Foster City |
ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE
|
US6030358A
(en)
*
|
1997-08-08 |
2000-02-29 |
Odland; Rick Matthew |
Microcatheter and method for site specific therapy
|
US6042909A
(en)
*
|
1997-09-03 |
2000-03-28 |
Circe Biomedical, Inc. |
Encapsulation device
|
GB2329840C
(en)
*
|
1997-10-03 |
2007-10-05 |
Johnson & Johnson Medical |
Biopolymer sponge tubes
|
US7687057B2
(en)
|
1998-01-09 |
2010-03-30 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
In vitro micro-organs, and uses related thereto
|
EP1064382B1
(en)
|
1998-03-17 |
2008-08-20 |
Genentech, Inc. |
Polypeptides homologous to vegf and bmp1
|
US7157083B2
(en)
*
|
1998-04-17 |
2007-01-02 |
Surrogate Pharmaceutical Pathways, Llc |
Compositions and methods for treating retroviral infections
|
US6463317B1
(en)
|
1998-05-19 |
2002-10-08 |
Regents Of The University Of Minnesota |
Device and method for the endovascular treatment of aneurysms
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US6344541B1
(en)
*
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
US6291516B1
(en)
|
1999-01-13 |
2001-09-18 |
Curis, Inc. |
Regulators of the hedgehog pathway, compositions and uses related thereto
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
US7708993B2
(en)
*
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
JP5000804B2
(en)
|
1999-02-03 |
2012-08-15 |
アムジエン・インコーポレーテツド |
Novel polypeptides involved in immune responses
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
US7396809B1
(en)
|
1999-02-10 |
2008-07-08 |
Curis, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
US7745216B2
(en)
*
|
1999-02-10 |
2010-06-29 |
Curis, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6361771B1
(en)
|
1999-04-06 |
2002-03-26 |
Neurotech S.A. |
ARPE-19 as a platform cell line for encapsulated cell-based delivery
|
US20070071734A1
(en)
*
|
1999-04-06 |
2007-03-29 |
Weng Tao |
ARPE-19 as platform cell line for encapsulated cell-based delivery
|
US6176242B1
(en)
|
1999-04-30 |
2001-01-23 |
Medtronic Inc |
Method of treating manic depression by brain infusion
|
US6109269A
(en)
*
|
1999-04-30 |
2000-08-29 |
Medtronic, Inc. |
Method of treating addiction by brain infusion
|
MXPA01013458A
(en)
|
1999-06-25 |
2002-07-30 |
Genentech Inc |
HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES.
|
AU5423300A
(en)
*
|
1999-06-25 |
2001-01-31 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Method of inducing angiogenesis by micro-organs
|
US7459540B1
(en)
*
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7408047B1
(en)
*
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
US20050239061A1
(en)
*
|
2000-03-01 |
2005-10-27 |
Marshall William S |
Identification and use of effectors and allosteric molecules for the alteration of gene expression
|
TWI322154B
(en)
|
2000-03-16 |
2010-03-21 |
Amgen Inc |
Il-17 receptor like molecules and uses thereof
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
US7115653B2
(en)
*
|
2000-03-30 |
2006-10-03 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US8852937B2
(en)
*
|
2000-03-30 |
2014-10-07 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US6613798B1
(en)
|
2000-03-30 |
2003-09-02 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US20050070578A1
(en)
*
|
2000-03-30 |
2005-03-31 |
Baxter Anthony David |
Small organic molecule regulators of cell proliferation
|
US6683108B1
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Agonists of hedgehog signaling pathways and uses related thereto
|
US6478776B1
(en)
|
2000-04-05 |
2002-11-12 |
Biocardia, Inc. |
Implant delivery catheter system and methods for its use
|
WO2001077342A1
(en)
|
2000-04-11 |
2001-10-18 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
AU6836301A
(en)
|
2000-06-20 |
2002-01-02 |
Idec Pharma Corp |
Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US20090209831A1
(en)
*
|
2000-06-28 |
2009-08-20 |
Nexgen Medical Systems, Incorporated |
Imaging methods for visualizing implanted living cells
|
ES2317917T3
(en)
|
2000-06-28 |
2009-05-01 |
Amgen Inc. |
TIMICA STROMAL LYMPHOPYETINE RECEPTOR MOLECULES AND THEIR USES OF THE SAME.
|
AU2001271618B8
(en)
*
|
2000-06-28 |
2006-04-27 |
Amgen, Inc. |
B7-Like molecules and uses thereof
|
EP1978090A1
(en)
|
2000-08-09 |
2008-10-08 |
ES Cell International Pte Ltd. |
Pancreatic progenitor cells
|
US6908732B2
(en)
|
2000-10-13 |
2005-06-21 |
President & Fellows Of Harvard College |
Compounds and methods for regulating cell differentiation
|
US6871098B2
(en)
*
|
2000-10-30 |
2005-03-22 |
Medtronic, Inc. |
Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
|
EP1337634A2
(en)
|
2000-11-28 |
2003-08-27 |
Amgen Inc. |
Novel polypeptides involved in immune response
|
CN1568195B
(en)
*
|
2000-12-14 |
2011-03-02 |
安米林药品公司 |
Peptide YY and peptide YY agonists for treatment of metabolic disorders
|
CZ298160B6
(en)
*
|
2001-01-18 |
2007-07-11 |
|
Apparatus for inducing an immune response in cancer therapy
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
EP2316463B1
(en)
*
|
2001-02-14 |
2017-04-12 |
Anthrogenesis Corporation |
Tissue matrices comprising placental stem cells, and methods of making them
|
DK2000545T3
(en)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of lung tumor
|
EP1414517A4
(en)
*
|
2001-06-26 |
2008-02-06 |
Photomed Technologies Inc |
Multiple wavelength illuminator
|
IL159512A0
(en)
|
2001-06-26 |
2004-06-01 |
Abgenix Inc |
Antibodies to opgl
|
EP1411769A4
(en)
*
|
2001-07-09 |
2004-12-29 |
Medgenics Inc |
Efficient methods for assessing and validating candidate protein-based therapeutic molecules encoded by nucleic acid sequences of interest
|
EP1639972B1
(en)
|
2001-08-01 |
2013-09-11 |
Anecova SA |
Intrauterine device
|
EP2382982A3
(en)
|
2001-08-24 |
2012-02-22 |
Neuren Pharmaceuticals Limited |
Neural regeneration peptide and methods for their use in treatment of brain damage
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
EP2174953A1
(en)
|
2001-09-18 |
2010-04-14 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US8501396B2
(en)
|
2001-11-05 |
2013-08-06 |
Medgenics Medical Israel Ltd. |
Dermal micro-organs, methods and apparatuses for producing and using the same
|
US7468242B2
(en)
|
2001-11-05 |
2008-12-23 |
Medgenics, Inc. |
Dermal micro organs, methods and apparatuses for producing and using the same
|
US8088568B2
(en)
|
2001-11-05 |
2012-01-03 |
Medgentics, Inc. |
Dermal micro-organs, methods and apparatuses for producing and using the same
|
US6758828B2
(en)
|
2001-12-10 |
2004-07-06 |
Regents Of The University Of Minnesota |
Catheter for cell delivery in tissue
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7662924B2
(en)
*
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US20040025194A1
(en)
*
|
2002-02-22 |
2004-02-05 |
Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US7718776B2
(en)
*
|
2002-04-05 |
2010-05-18 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
JP2005536190A
(en)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
Compositions and methods for tumor diagnosis and treatment
|
WO2003088970A2
(en)
|
2002-04-22 |
2003-10-30 |
Johns Hopkins University School Of Medicine |
Modulators of hedgehog signaling pathways, compositions and uses related thereto
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003251397B2
(en)
|
2002-06-05 |
2009-10-01 |
Genentech, Inc. |
Compositions and methods for liver growth and liver protection
|
CA2486252C
(en)
*
|
2002-06-07 |
2012-07-24 |
Genentech, Inc. |
Methods for screening for agents that modulate hepatocellular carcinoma development
|
WO2003105763A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Amylin Pharmaceuticals, Inc. |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
JP2005533102A
(en)
*
|
2002-07-12 |
2005-11-04 |
イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム |
Method and apparatus for inducing biological processes by micro-organs
|
EP1585966B8
(en)
|
2002-07-15 |
2012-03-07 |
F. Hoffmann-La Roche AG |
Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
|
AU2003275240A1
(en)
*
|
2002-09-24 |
2004-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for soluble cpg15
|
PT1572106E
(en)
|
2002-11-15 |
2010-06-17 |
Novartis Vaccines & Diagnostic |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
CA2519241A1
(en)
|
2003-04-01 |
2004-11-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2004091657A2
(en)
|
2003-04-09 |
2004-10-28 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
EP3254710B1
(en)
*
|
2003-04-11 |
2019-05-22 |
Etex Corporation |
Osteoinductive bone material
|
US7241283B2
(en)
*
|
2003-04-25 |
2007-07-10 |
Ad-Tech Medical Instrument Corp. |
Method for intracranial catheter treatment of brain tissue
|
CA2748659A1
(en)
|
2003-05-01 |
2004-11-18 |
Medgenics Inc. |
Dermal micro organs, methods and apparatuses for producing and using the same
|
EP1633784B1
(en)
|
2003-05-09 |
2011-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
CA2525969A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
CA2526080A1
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
NZ544263A
(en)
|
2003-06-10 |
2009-04-30 |
Nsgene As |
Improved secretion of neublastin
|
CA2432810A1
(en)
*
|
2003-06-19 |
2004-12-19 |
Andres M. Lozano |
Method of treating depression, mood disorders and anxiety disorders by brian infusion
|
US8501473B2
(en)
|
2003-07-16 |
2013-08-06 |
Evotec International Gmbh |
Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
RU2370775C2
(en)
|
2003-07-29 |
2009-10-20 |
Дженентек, Инк. |
Analysis of neutralising antibodies and its application
|
CA2538342C
(en)
|
2003-09-12 |
2013-01-08 |
Tercica, Inc. |
Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
|
US20050187175A1
(en)
*
|
2003-09-30 |
2005-08-25 |
Elly Nedivi |
Methods and compositions for CPG15-2
|
DK1677833T3
(en)
|
2003-10-20 |
2010-05-17 |
Nsgene As |
Virus vector for use in in vivo gene therapy of Parkinson's disease
|
ES2493016T3
(en)
|
2003-11-17 |
2014-09-11 |
Genentech, Inc. |
Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or a cytotoxic agent and methods for the treatment of tumors of hematopoietic origin
|
TR201815885T4
(en)
|
2004-01-07 |
2018-11-21 |
Novartis Vaccines & Diagnostics Inc |
M-csf specific monoclonal antibodies and their use.
|
ATE409741T1
(en)
*
|
2004-01-19 |
2008-10-15 |
Nsgene As |
NERVE GROWTH FACTOR SECRETING HUMAN THERAPEUTIC CELLS
|
EP1789440A4
(en)
*
|
2004-02-11 |
2008-03-12 |
Amylin Pharmaceuticals Inc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
AU2005229434B2
(en)
|
2004-03-30 |
2010-09-30 |
Nsgene A/S |
Therapeutic use of a growth factor, NsG33
|
AU2005249365B2
(en)
*
|
2004-04-15 |
2011-04-07 |
Etex Corporation |
Delayed-setting calcium phosphate pastes
|
EP1742660A2
(en)
*
|
2004-04-16 |
2007-01-17 |
Genentech, Inc. |
Treatment of disorders
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
US7313442B2
(en)
*
|
2004-04-30 |
2007-12-25 |
Advanced Neuromodulation Systems, Inc. |
Method of treating mood disorders and/or anxiety disorders by brain stimulation
|
WO2005113596A2
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
MXPA06014069A
(en)
|
2004-06-04 |
2007-04-25 |
Genentech Inc |
Method for treating multiple sclerosis.
|
CA2571218C
(en)
|
2004-06-17 |
2015-11-03 |
William D. Carlson |
Tdf-related compounds and analogs thereof
|
US20090136552A1
(en)
*
|
2004-07-30 |
2009-05-28 |
Mette Gronborg |
Growth factors nsg28, nsg30, and nsg32
|
US20070072294A1
(en)
*
|
2004-09-30 |
2007-03-29 |
Doronin Sergey V |
Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division
|
CA3066594A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Georgia Tech Research Corporation |
Microencapsulation of cells in hydrogels using electrostatic potentials
|
EP1799659A1
(en)
|
2004-10-13 |
2007-06-27 |
PTC Therapeutics, Inc. |
Compounds for nonsense suppression, and methods for their use
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
US8119398B2
(en)
*
|
2004-12-30 |
2012-02-21 |
Primegen Biotech Llc |
Adipose-derived stem cells for tissue regeneration and wound healing
|
ES2343746T3
(en)
|
2005-01-07 |
2010-08-09 |
Diadexus, Inc. |
OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE.
|
US7713542B2
(en)
|
2005-01-14 |
2010-05-11 |
Ada Foundation |
Three dimensional cell protector/pore architecture formation for bone and tissue constructs
|
WO2006078307A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
WO2006081171A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
US20060188509A1
(en)
|
2005-02-23 |
2006-08-24 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
AU2006218642A1
(en)
*
|
2005-03-01 |
2006-09-08 |
Advanced Neuromodulation Systems, Inc. |
Method of treating depression, mood disorders and anxiety disorders using neuromodulation
|
US20060212090A1
(en)
*
|
2005-03-01 |
2006-09-21 |
Functional Neuroscience Inc. |
Method of treating cognitive disorders using neuromodulation
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
CN103356705B
(en)
|
2005-03-31 |
2015-09-30 |
斯丹姆涅恩有限公司 |
Prepare the method for the medicine in order to treat burn wound
|
EP1869162A1
(en)
*
|
2005-04-01 |
2007-12-26 |
NsGene A/S |
A human immortalised neural precursor cell line
|
EP2316859A1
(en)
|
2005-04-09 |
2011-05-04 |
Fusion Antibodies Limited |
Cathepsin S antibody
|
EP1885454A2
(en)
|
2005-05-04 |
2008-02-13 |
DeveloGen Aktiengesellschaft |
Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
|
EP1877434A2
(en)
*
|
2005-05-04 |
2008-01-16 |
Nautilus Biotech |
Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
|
WO2006119510A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Receptor Biologix, Inc. |
Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
EP1883446B8
(en)
*
|
2005-05-17 |
2017-11-15 |
Gloria Therapeutics Sarl |
An implantable therapy system for treating a living being with an active factor
|
MX2007016032A
(en)
|
2005-06-21 |
2008-03-10 |
Xoma Technology Ltd |
Il-1 beta binding antibodies and fragments thereof.
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
JP5657862B2
(en)
*
|
2005-07-28 |
2015-01-21 |
ノバルティス アーゲー |
Use of antibodies against M-CSF
|
EP1940457B1
(en)
*
|
2005-10-21 |
2012-12-12 |
Catalyst Biosciences, Inc. |
Modified proteases that inhibit complement activation
|
US8986781B2
(en)
*
|
2005-10-27 |
2015-03-24 |
Corning Incorporated |
Immobilized multi-layer artificial membrane for permeability measurements (PAMPA)
|
US20080286250A1
(en)
*
|
2005-10-28 |
2008-11-20 |
Jens Tornoe |
Implantable Biocompatible Immunoisolatory Vehicle for Delivery of Gdnf
|
JP2009515520A
(en)
*
|
2005-11-10 |
2009-04-16 |
レセプター バイオロジックス, インコーポレイテッド |
Hepatocyte growth factor intron fusion protein
|
US8147860B2
(en)
|
2005-12-06 |
2012-04-03 |
Etex Corporation |
Porous calcium phosphate bone material
|
DE602005023550D1
(en)
|
2005-12-14 |
2010-10-21 |
Licentia Ltd |
Uses of a neurotrophic factor
|
CA2635534C
(en)
|
2005-12-30 |
2014-07-29 |
Neurotech Usa Inc. |
Micronized device for the delivery of biologically active molecules and methods of use thereof
|
AU2007212110A1
(en)
|
2006-02-02 |
2007-08-16 |
Innovative Bio Therapies |
An extracorporeal cell-based therapeutic device and delivery system
|
US20090081296A1
(en)
*
|
2006-02-02 |
2009-03-26 |
Humes H David |
Extracorporeal cell-based therapeutic device and delivery system
|
US7884078B2
(en)
*
|
2006-02-10 |
2011-02-08 |
Massachusetts Institute Of Technology |
CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
|
GB0604187D0
(en)
*
|
2006-03-02 |
2006-04-12 |
Fusion Antibodies Ltd |
Peptide and uses thereof
|
EP2389951A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
WO2007110231A2
(en)
*
|
2006-03-28 |
2007-10-04 |
Nautilus Biotech, S.A. |
MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
CA2648947A1
(en)
*
|
2006-04-10 |
2007-11-15 |
Fusion Antibodies Limited |
Therapy targeting cathepsin s
|
GB0620255D0
(en)
*
|
2006-10-12 |
2006-11-22 |
Fusion Antibodies Ltd |
Antibody and uses thereof
|
CN101479295A
(en)
|
2006-05-04 |
2009-07-08 |
健泰科生物技术公司 |
Methods and compositions relating to ZPA polypeptides
|
US20100030102A1
(en)
*
|
2006-05-15 |
2010-02-04 |
David Poston |
Active Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to Patients
|
US7998128B2
(en)
|
2006-05-15 |
2011-08-16 |
Therataxis, LLC. |
Active delivery and flow redirection: novel devices and method of delivery of materials to patients
|
EP2423306A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
KR20170014023A
(en)
|
2006-07-05 |
2017-02-07 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
Protease screening methods and proteases identified thereby
|
KR101433544B1
(en)
|
2006-08-18 |
2014-08-27 |
노바르티스 아게 |
Prlr-specific antibody and uses thereof
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
US9155749B2
(en)
*
|
2006-09-14 |
2015-10-13 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
CA2683109A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Fusion Antibodies Limited |
Combination therapy
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US20090214474A1
(en)
*
|
2006-11-01 |
2009-08-27 |
Barbara Brooke Jennings |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP2104513B1
(en)
|
2006-11-27 |
2015-05-20 |
diaDexus, Inc. |
Ovr110 antibody compositions and methods of use
|
WO2008065372A2
(en)
|
2006-11-28 |
2008-06-05 |
Nautilus Biotech, S.A. |
Modified erythropoietin polypeptides and uses thereof for treatment
|
EA200900767A1
(en)
|
2006-12-07 |
2009-12-30 |
Новартис Аг |
ANTAGONISTIC ANTIBODIES AGAINST EPHB3
|
ES2623141T3
(en)
|
2007-01-17 |
2017-07-10 |
Noveome Biotherapeutics, Inc. |
New methods to modulate inflammatory and / or immune responses
|
AR065083A1
(en)
*
|
2007-02-02 |
2009-05-13 |
Amgen Inc |
HEPCIDINE, HEPCIDINE ANTAGONISTS AND METHODS OF USE
|
PE20090681A1
(en)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
PREDICTION OF RESPONSE TO A HER INHIBITOR
|
KR20150067772A
(en)
|
2007-04-13 |
2015-06-18 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
Modified factor VII polypeptides and uses thereof
|
US20100086525A1
(en)
*
|
2007-05-03 |
2010-04-08 |
Zaret Kenneth S |
Compositions and Methods for Altering Pancreas or Liver Function
|
WO2008137280A1
(en)
*
|
2007-05-03 |
2008-11-13 |
Fox Chase Cancer Center |
Compositions and methods for altering pancreas or liver function
|
WO2008144232A2
(en)
|
2007-05-18 |
2008-11-27 |
The Johns Hopkins University |
A treatment simulator for brain diseases and method of use thereof
|
ES2528922T3
(en)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Humanized and immunoconjugate anti-CD79b antibodies and methods of use
|
DK2474557T3
(en)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b antibodies and immune conjugates and methods of use
|
FI20070808A0
(en)
|
2007-10-25 |
2007-10-25 |
Mart Saarma |
Split variants of GDNF and uses thereof
|
WO2009073891A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Northstar Neuroscience, Inc. |
Systems and methods for providing targeted neural stimulation therapy to address neurological disorders, including neuropyschiatric and neuropyschological disorders
|
WO2009085200A2
(en)
|
2007-12-21 |
2009-07-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
AU2009210636B2
(en)
|
2008-01-31 |
2014-08-28 |
Genentech, Inc. |
Anti-CD79b antibodies and immunoconjugates and methods of use
|
US20090196854A1
(en)
*
|
2008-02-04 |
2009-08-06 |
Kytos Biosystems S.A. |
Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
|
TWI465247B
(en)
|
2008-04-11 |
2014-12-21 |
Catalyst Biosciences Inc |
Factor vii polypeptides that are modified and uses thereof
|
GB0807018D0
(en)
*
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
FI20080326A0
(en)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotrophic factor MANF and its uses
|
JOP20190083A1
(en)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
Fgf21 mutant fusion polypeptides and uses thereof
|
US9144584B2
(en)
|
2008-06-11 |
2015-09-29 |
Cell4Vet Corporation |
Adipose tissue-derived stem cells for veterinary use
|
CN102171332A
(en)
*
|
2008-06-18 |
2011-08-31 |
创新生物制剂疗法公司 |
Methods for enhanced propagation of cells
|
US8052970B2
(en)
*
|
2008-06-30 |
2011-11-08 |
The Regents Of The University Of Michigan |
Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
|
EP2460827A1
(en)
|
2008-06-30 |
2012-06-06 |
The Trustees Of The University Of Pennsylvania |
Fusion proteins comprising Fn14 and an inhibitory protein
|
ES2332169B1
(en)
|
2008-07-24 |
2010-10-25 |
Universidad Del Pais Vasco |
EMPLOYMENT OF MICROPARTICLES THAT INCLUDE GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.
|
TW201014605A
(en)
*
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
PE20120021A1
(en)
|
2008-10-10 |
2012-02-10 |
Amgen Inc |
MUTANTS FGF21
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
AU2010206374B2
(en)
*
|
2009-01-23 |
2013-01-17 |
Gloriana Therapeutics Sarl |
Improved cell lines and their use in encapsulated cell biodelivery
|
WO2010083842A2
(en)
|
2009-01-23 |
2010-07-29 |
Nsgene A/S |
Expression of neuropeptides in mammalian cells
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
AU2010224094A1
(en)
|
2009-03-13 |
2011-09-22 |
The Trustees Of The University Of Pennsylvania |
OX40/TRAIL fusion proteins
|
US8734796B2
(en)
|
2009-03-20 |
2014-05-27 |
Amgen Inc. |
Carrier immunoglobulins
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
US20100272780A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Vincent Ling |
CELL LINES THAT PRODUCE PROSTAGLANDIN F2 ALPHA (PGF2a) AND USES THEREOF
|
FI3248610T3
(en)
|
2009-05-05 |
2024-01-18 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
MX2011011815A
(en)
|
2009-05-05 |
2012-01-27 |
Amgen Inc |
Fgf21 mutants and uses thereof.
|
EP2443145A1
(en)
*
|
2009-06-17 |
2012-04-25 |
Amgen, Inc |
Chimeric fgf19 polypeptides and uses thereof
|
CN102575298A
(en)
|
2009-08-14 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
Biological markers for monitoring patient response to VEGF antagonists
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
SG179070A1
(en)
|
2009-09-11 |
2012-04-27 |
Genentech Inc |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
CA2776748A1
(en)
*
|
2009-10-08 |
2011-04-14 |
Neurotech Usa, Inc. |
Use of pedf in an encapsulated cell-based delivery system
|
CN102711826B
(en)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
For the method and composition that the HEPSIN for regulating and controlling macrophage-stimulating albumen is activated
|
EP2501407A1
(en)
|
2009-11-20 |
2012-09-26 |
Amgen Inc. |
Anti-orai1 antigen binding proteins and uses thereof
|
CA2781887C
(en)
|
2009-11-30 |
2018-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2506861A1
(en)
*
|
2009-12-02 |
2012-10-10 |
Amgen Inc. |
Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
|
UA109888C2
(en)
|
2009-12-07 |
2015-10-26 |
|
ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
AU2010336485B2
(en)
|
2009-12-23 |
2015-03-26 |
Genentech, Inc. |
Anti-Bv8 antibodies and uses thereof
|
EP2538981B1
(en)
|
2010-02-23 |
2017-12-20 |
F. Hoffmann-La Roche AG |
Compositions and methods for the diagnosis and treatment of tumor
|
JP2013523184A
(en)
|
2010-04-15 |
2013-06-17 |
アムジエン・インコーポレーテツド |
Human FGF receptor and β-KLOTHO binding protein
|
US8993532B2
(en)
|
2010-04-23 |
2015-03-31 |
Cold Spring Harbor Laboratory |
Structurally designed shRNAs
|
MA34291B1
(en)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
|
US8785395B2
(en)
|
2010-05-03 |
2014-07-22 |
The Texas A & M University System |
Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011159758A2
(en)
|
2010-06-15 |
2011-12-22 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
WO2012010548A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
EP2596362A1
(en)
|
2010-07-19 |
2013-05-29 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
WO2012040518A2
(en)
|
2010-09-22 |
2012-03-29 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
CA2812057A1
(en)
|
2010-09-28 |
2012-04-05 |
Kahr Medical Ltd. |
Compositions and methods for treatment of hematological malignancies
|
EP2446898A1
(en)
|
2010-09-30 |
2012-05-02 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of growth hormone to enhance the immune response in immunosuppressed patients
|
KR101886029B1
(en)
|
2010-10-01 |
2018-08-07 |
호바 세라퓨틱스 에이피에스 |
Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
TWI557135B
(en)
|
2010-11-03 |
2016-11-11 |
介控生化科技公司 |
Modified factor ix polypeptides and uses thereof
|
JP2014506119A
(en)
|
2010-12-02 |
2014-03-13 |
ニューロテック ユーエスエー, インコーポレイテッド |
Cell lines secreting anti-angiogenic antibody scaffolds and soluble receptors and uses thereof
|
WO2012088254A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
|
KR101242656B1
(en)
*
|
2011-03-04 |
2013-03-20 |
포항공과대학교 산학협력단 |
Artificial pancreatic islet cell structure and manufacturing method thereof
|
EP2699593B2
(en)
|
2011-04-20 |
2020-11-04 |
University of Washington Through Its Center for Commercialization |
Beta-2 microglobulin-deficient cells
|
CN107596346A
(en)
|
2011-09-05 |
2018-01-19 |
霍巴治疗公司 |
Allodynia, hyperalgia, the treatment of spontaneous pain and phantom pain
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
MX356802B
(en)
|
2012-01-13 |
2018-06-13 |
Genentech Inc |
Biological markers for identifying patients for treatment with vegf antagonists.
|
EP2634307B1
(en)
|
2012-03-02 |
2016-05-11 |
Valmet Technologies, Inc. |
Method for modernizing a supercalender and a modernized supercalender
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
RU2666627C2
(en)
|
2012-03-30 |
2018-09-11 |
Дженентек, Инк. |
Methods of diagnosis and composition for cancer treatment
|
CA3085032A1
(en)
|
2012-04-17 |
2013-10-24 |
University Of Washington Through Its Center For Commercialization |
Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
|
EP2854884A1
(en)
|
2012-05-30 |
2015-04-08 |
Neurotech USA, Inc. |
Cryopreserved implantable cell culture devices and uses thereof
|
NZ703148A
(en)
|
2012-07-25 |
2016-08-26 |
Catalyst Biosciences Inc |
Modified factor x polypeptides and uses thereof
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(en)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
WO2014173441A1
(en)
*
|
2013-04-24 |
2014-10-30 |
Nestec S.A. |
Encapsulation device
|
US9907496B1
(en)
|
2013-06-25 |
2018-03-06 |
National Technology & Engineering Solutions Of Sandia, Llc |
Optoelectronic system and apparatus for connection to biological systems
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
KR20160086819A
(en)
|
2013-09-11 |
2016-07-20 |
뉴로테크 유에스에이, 인코포레이티드. |
Encapsulated cell therapy cartridge
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
EP3102197B1
(en)
|
2014-02-04 |
2018-08-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
WO2016011052A1
(en)
|
2014-07-14 |
2016-01-21 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US9775978B2
(en)
|
2014-07-25 |
2017-10-03 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having a retaining member
|
US9764122B2
(en)
|
2014-07-25 |
2017-09-19 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having an occluding member
|
EP3206707B1
(en)
|
2014-10-13 |
2020-12-02 |
University of Maryland, Baltimore |
Fc-ela-32 and its use in the treatment of cardiac conditions
|
CN107208076A
(en)
|
2014-10-17 |
2017-09-26 |
科达制药 |
Butyrylcholine esterase amphoteric ion polymer conjugate
|
EP3237639A2
(en)
|
2014-12-23 |
2017-11-01 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
SG11201704852SA
(en)
|
2014-12-24 |
2017-07-28 |
Genentech Inc |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US10456356B2
(en)
|
2015-05-27 |
2019-10-29 |
Neurotech Usa, Inc. |
Use of encapsulated cell therapy for treatment of ophthalmic disorders
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
KR20180020169A
(en)
|
2015-06-24 |
2018-02-27 |
에프. 호프만-라 로슈 아게 |
Anti-transferrin receptor antibody with adjusted affinity
|
AR106189A1
(en)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
|
CN114057885A
(en)
|
2015-10-02 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use
|
KR20180075537A
(en)
|
2015-10-06 |
2018-07-04 |
제넨테크, 인크. |
Methods for treating multiple sclerosis
|
US10076650B2
(en)
|
2015-11-23 |
2018-09-18 |
Warsaw Orthopedic, Inc. |
Enhanced stylet for drug depot injector
|
EP3397276A4
(en)
|
2015-12-30 |
2019-12-18 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
KR20190007026A
(en)
|
2016-05-17 |
2019-01-21 |
제넨테크, 인크. |
Substrate Gene Properties for Diagnosis and Use in Immunotherapy
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
USD802755S1
(en)
|
2016-06-23 |
2017-11-14 |
Warsaw Orthopedic, Inc. |
Drug pellet cartridge
|
JP7054523B2
(en)
*
|
2016-06-28 |
2022-04-14 |
国立研究開発法人農業・食品産業技術総合研究機構 |
Cell encapsulation device and its use
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
US10434261B2
(en)
|
2016-11-08 |
2019-10-08 |
Warsaw Orthopedic, Inc. |
Drug pellet delivery system and method
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
EP3615569A1
(en)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
BR112019027583A2
(en)
|
2017-06-22 |
2020-10-06 |
Catalyst Biosciences, Inc. |
modified membrane-like serine protease 1 (mtsp-1) polypeptides and methods of use
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
MX2020003371A
(en)
*
|
2017-09-29 |
2020-10-01 |
Semma Therapeutics Inc |
Cell housing device.
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
AU2019275404A1
(en)
|
2018-05-21 |
2020-12-03 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
WO2019235581A1
(en)
|
2018-06-06 |
2019-12-12 |
国立大学法人大阪大学 |
METHOD FOR TREATING AND/OR PREVENTING Regnase-1-RELATED DISEASE
|
DE102018006061A1
(en)
*
|
2018-08-01 |
2020-02-06 |
Universität Duisburg-Essen |
implant
|
JP2022516725A
(en)
|
2018-12-28 |
2022-03-02 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
Modified urokinase-type plasminogen activator polypeptide and usage
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
EP3947441A1
(en)
|
2019-03-27 |
2022-02-09 |
UMC Utrecht Holding B.V. |
Engineered iga antibodies and methods of use
|
EP3833381B1
(en)
|
2019-08-15 |
2022-08-03 |
Catalyst Biosciences, Inc. |
Modified factor vii polypeptides for subcutaneous administration
|
EP4041312A4
(en)
|
2019-10-10 |
2023-12-20 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021087476A1
(en)
*
|
2019-11-01 |
2021-05-06 |
Neurotech Usa, Inc. |
System, apparatuses, devices, and methods for packaging an analyte diffusive implantable device
|
WO2022011081A1
(en)
|
2020-07-09 |
2022-01-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cell lines that produce human retinoschisin proteins and uses thereof
|
CN115591025B
(en)
*
|
2022-11-09 |
2024-01-02 |
深圳先进技术研究院 |
Nerve regulation device, preparation method and application thereof
|